A Phase 3 Randomized Double-Blind Placebo-Controlled Program to Evaluate the Efficacy and Safety of MK-7240 in Participants with Moderately to Severely Active Ulcerative Colitis

Brief description of study

This trial is testing MK-7240 in people with moderate to severely active ulcerative colitis (UC). This trial will compare MK-7240 to placebo. A placebo looks like a trial drug, but it has no active ingredients.

The purpose of this trial is to:

Test the safety of the trial drug, MK-7240
See how well the trial drug works compared to placebo

Clinical Study Identifier: s24-00618

ClinicalTrials.gov Identifier: NCT06052059

Principal Investigator: David P Hudesman.

Other Investigators: Elie S Al Kazzi, Shannon Chang, Adam Faye, Simon J Hong, Ariela Holmer, Jordan E Axelrad.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies